NCT07218900View on ClinicalTrials.gov

A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

October 24, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Dyslipidaemia
Interventions
DRUG

Placebo

Administered orally as tablets

DRUG

AZD0780

Administered orally as tablets

DRUG

Rosuvastatin

Administered orally as tablets

Trial Locations (8)

105554

Research Site, Moscow

111539

Research Site, Moscow

117292

Research Site, Moscow

121552

Research Site, Moscow

153012

Research Site, Ivanovo

194156

Research Site, Saint Petersburg

410054

Research Site, Saratov

624002

Research Site, Aramil

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY